The NextSeq™ 1000/2000 Experience

30 August 2021

Hear from researchers who are currently using the NextSeq 1000/2000 sequencing platforms for SARS-CoV-2 genomic surveillance, CRISPR screening, single cell RNA Seq, and more. Learn how they’re enriching their sequencing workflows with the ease of use, affordability, and efficiency of the NextSeq 1000/2000 systems. Learn more at https://www.illumina.com/NextSeq2000 Featured Researchers: Efrem Lim, PhD, Assistant Professor, Arizona State University School of Life Science, Biodesign Institute, Center for Fundamental and Applied Microbiomics Magdy Alabady, PhD, Director of Georgia Genomics and Bioinformatics Core Facility, Associate Research Scientist, Plant Biology Jasmine Amerasekera, Research Specialist, Scribe Therapeutics Illumina sequencing and array technologies fuel advancements in life science research, translational and consumer genomics, and molecular diagnostics. M-US-00105

Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see sapac.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.